Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Devey, P.
Right arrow Articles by Thomas, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Devey, P.
Right arrow Articles by Thomas, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1992) 30, 855-864
© 1992 The British Society for Antimicrobial Chemotherapy


research-article

Cost-effectiveness of single dose cefotaxime plus metronidazole compared with three doses each of cefuroxime plus metronidazole for the prevention of wound infection after colorectal surgery

Peter Deveya,*, Bill Lyncha, Mo Maleka, Derek Byrneb and Peter Thomasc

aPharmacoeconomics Research Centre, Universities of Dundee and St Andrews UK bDepartment of Surgery, Ninewells Hospital and Medical School Dundee DDJ 9SY cRoussel Laboratories Ltd Broadwater Park, North Orbital Road, Denham, Uxbridge, Middx UB9 5HP, UK

Received 4 March 1992; returned 9 July 1992; accepted 9 July 1992


*Correspondence to Dr P. Davey, Departnnt of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

The cost-effectiveness of prophylaxis for colonic surgery with single dose cefotaxime plus metronidazole has been compared with that of three doses each of cefuroxime plus metronidazole, by analysing data from a previously published study supplemented with additional data on the hospital and community costs of wound infection after colonic surgery. The original trial included 942 patients having elective colonic surgery in 14 hospitals. The data on costs of wound infection were collected from a further 124 patients undergoing elective colonic surgery at Ninewells Hospital. All these patients received a three dose regimen of cefuroxime plus metronidazole. The Dundee patients received three injections of 0·75 g cefuroxime at 8-hourly intervals whereas the trial patients received a single dose of 1·5 g followed by two further doses of 0·75g at 8-hourly intervals. The cefuroxime prophylaxis regimen used in the trial cost {lambda}24.16 per patient more than the cefotaxime regimen. The components of the excess cost were drugs ({lambda}15.18), equipment ({lambda}6.14) and staff time ({lambda}2.84). The median cost to the hospital of a wound infection was {lambda}978.04 (95% CI {lambda}482.04 to {lambda}1521.22). The components of the hospital cost of wound infection were: hotel costs {lambda}858 (88%), dressing costs {lambda}83.02 (8%) and drug costs (excluding prophylaxis) {lambda}37.02 (4%). Only five patients received additional antibiotic treatment in the community, and only one required home visits from the District Nurse. Applying the difference in costs of prophylaxis as {lambda}21 (costs of drugs plus equipment) and the cost per wound infection as {lambda}1000 to the observed wound infection rate of 7% in the cefuroxime group, the wound infection rate in the cefotaxime group would have to be 2·1% higher for the two regimens to be equally cost-effective. The probability that such a difference in efficacy exists is 0-088. A model was developed to calculate the probability of equal cost-effectiveness over a range of costs of wound infection.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.